Barclays PLC Regulus Therapeutics Inc. Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
A detailed history of Barclays PLC transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Barclays PLC holds 84,477 shares of RGLS stock, worth $119,112. This represents 0.0% of its overall portfolio holdings.
Number of Shares
84,477
Previous 84,477
-0.0%
Holding current value
$119,112
Previous $132,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding RGLS
# of Institutions
74Shares Held
56.5MCall Options Held
79.3KPut Options Held
20.3K-
Federated Hermes, Inc. Pittsburgh, PA12.9MShares$18.1 Million0.05% of portfolio
-
Nea Management Company, LLC Timonium, MD6.47MShares$9.12 Million0.78% of portfolio
-
Vivo Capital, LLC Palo Alto, CA5MShares$7.05 Million1.15% of portfolio
-
Octagon Capital Advisors LP New York, NY4.26MShares$6.01 Million1.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.09MShares$5.77 Million0.0% of portfolio
About Regulus Therapeutics Inc.
- Ticker RGLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,634,400
- Market Cap $20.6M
- Description
- Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...